Truist Securities Reiterates Buy on Allogene Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Allogene Therapeutics (NASDAQ:ALLO) but lowered the price target from $17 to $14.
August 09, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has reiterated its Buy rating on Allogene Therapeutics but lowered the price target from $17 to $14.
The reiteration of the Buy rating is positive, but the lowered price target may temper investor enthusiasm. Overall, the impact is neutral as the positive rating balances the lower target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100